HC Wainwright Cuts Earnings Estimates for Oruka Therapeutics

Oruka Therapeutics, Inc. (NASDAQ:ORKA) – Equities researchers at HC Wainwright lowered their FY2026 earnings per share estimates for shares of Oruka Therapeutics in a research report issued on Tuesday, November 10th. HC Wainwright analyst M. Kapoor now forecasts that the company will earn ($2.69) per share for the year, down from their prior estimate of ($2.54). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Oruka Therapeutics’ current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Oruka Therapeutics’ Q4 2026 earnings at ($0.74) EPS, Q1 2027 earnings at ($0.76) EPS, Q2 2027 earnings at ($0.79) EPS, Q3 2027 earnings at ($0.82) EPS, Q4 2027 earnings at ($0.85) EPS and FY2027 earnings at ($3.22) EPS.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings data on Monday, November 9th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.03).

A number of other brokerages have also issued reports on ORKA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oruka Therapeutics in a research note on Tuesday, October 13th. BTIG Research restated a “buy” rating and set a $151.00 price target on shares of Oruka Therapeutics in a report on Tuesday. Mizuho set a $120.00 price target on Oruka Therapeutics in a research report on Thursday, September 3rd. Piper Sandler reiterated an “overweight” rating on shares of Oruka Therapeutics in a research note on Wednesday, October 7th. Finally, Wedbush reissued an “outperform” rating and set a $165.00 price objective on shares of Oruka Therapeutics in a report on Tuesday, October 27th. Ten equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $133.00.

Oruka Therapeutics Price Performance

Shares of NASDAQ ORKA opened at $107.17 on Thursday. Oruka Therapeutics has a 52-week low of $25.23 and a 52-week high of $115.51. The business’s 50 day moving average is $89.12 and its two-hundred day moving average is $71.65.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Allspring Global Investments Holdings LLC raised its stake in shares of Oruka Therapeutics by 4.4% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 3,991 shares of the company’s stock worth $333,000 after buying an additional 168 shares during the last quarter. Algert Global LLC boosted its stake in Oruka Therapeutics by 3.5% in the 2nd quarter. Algert Global LLC now owns 5,380 shares of the company’s stock worth $512,000 after buying an additional 180 shares during the last quarter. AlphaCentric Advisors LLC boosted its position in shares of Oruka Therapeutics by 3.4% in the third quarter. AlphaCentric Advisors LLC now owns 6,752 shares of the company’s stock worth $562,000 after acquiring an additional 221 shares during the last quarter. GAMMA Investing LLC grew its stake in shares of Oruka Therapeutics by 201.6% during the 3rd quarter. GAMMA Investing LLC now owns 374 shares of the company’s stock valued at $31,000 after buying an additional 250 shares during the period. Finally, Nykredit A S acquired a new stake in Oruka Therapeutics during the second quarter worth about $29,000. 56.44% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, SVP Arjun Agarwal sold 9,999 shares of the business’s stock in a transaction dated Monday, October 12th. The shares were sold at an average price of $80.60, for a total transaction of $805,919.40. Following the transaction, the senior vice president directly owned 14,219 shares in the company, valued at $1,146,051.40. The trade was a 41.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Joana Goncalves sold 7,000 shares of the business’s stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $74.81, for a total value of $523,670.00. Following the transaction, the insider owned 31,771 shares in the company, valued at $2,376,788.51. The trade was a 18.05% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 169,950 shares of company stock valued at $15,426,080 over the last quarter. Corporate insiders own 23.49% of the company’s stock.

Recent Oruka Therapeutics Headlines

These are some of the ORKA headlines that stood out recently:

• Positive Sentiment: UBS also initiated or reiterated a Buy rating, adding another favorable analyst view. Oruka Therapeutics Receives a Buy from UBS
• Neutral Sentiment: Investors are looking ahead to 52-week data for ORKA-001 expected in December, with a Phase 3 trial start planned for 2027. The data could be an important pipeline catalyst. Oruka Expects ORKA-001 52-Week Data in December
• Negative Sentiment: HC Wainwright cut its quarterly and full-year EPS estimates for 2026 and 2027, including its FY2027 estimate from a loss of $2.82 to a loss of $3.22 per share. The firm maintained its Buy rating, but the deeper projected losses could weigh on sentiment.

Oruka Therapeutics Company Profile

Oruka Therapeutics is a clinical-stage biotechnology company developing long-acting antibody medicines for chronic inflammatory skin diseases. Its research focuses on pathways involved in conditions such as plaque psoriasis, with the goal of extending the time between treatments. The company’s pipeline includes ORKA-001, an antibody targeting interleukin-23 (IL-23), and ORKA-002, which targets interleukin-17A and interleukin-17F (IL-17A/F). Both programs are being developed as potential treatments for inflammatory skin conditions.